{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T07:09:48Z","timestamp":1780643388725,"version":"3.54.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jacl.2025.05.004","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T23:35:48Z","timestamp":1747352148000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Lomitapide-induced fatty liver is a reversible condition: Evidence from a case of familial chylomicronemia syndrome"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6514-2451","authenticated-orcid":false,"given":"Daniele","family":"Tramontano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele di","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Baratta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8359-6599","authenticated-orcid":false,"given":"Alessia Di","family":"Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4922-4318","authenticated-orcid":false,"given":"Nicholas","family":"Cocomello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Commodari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1006-4636","authenticated-orcid":false,"given":"Simone","family":"Bini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9801-4501","authenticated-orcid":false,"given":"Ilenia","family":"Minicocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Arca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9174-4667","authenticated-orcid":false,"given":"Laura","family":"D\u2019Erasmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jacl.2025.05.004_bib0001","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3390\/metabo13050621","article-title":"Severe hypertriglyceridaemia and chylomicronaemia syndrome-causes, clinical presentation, and therapeutic options","volume":"13","author":"Bashir","year":"2023","journal-title":"Metabolites"},{"issue":"11","key":"10.1016\/j.jacl.2025.05.004_bib0002","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11883-020-00885-1","article-title":"Familial chylomicronemia syndrome (FCS): recent data on diagnosis and treatment","volume":"22","author":"Gallo","year":"2020","journal-title":"Curr Atheroscler Rep"},{"issue":"12","key":"10.1016\/j.jacl.2025.05.004_bib0003","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1161\/ATVBAHA.119.313401","article-title":"Spectrum of mutations and long-term clinical outcomes in genetic chylomicronemia syndromes","volume":"39","author":"D'Erasmo","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"10.1016\/j.jacl.2025.05.004_bib0004","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11883-021-00967-8","article-title":"Rare treatments for rare dyslipidemias: new perspectives in the treatment of homozygous familial hypercholesterolemia (HoFH) and familial chylomicronemia syndrome (FCS)","volume":"23","author":"D'Erasmo","year":"2021","journal-title":"Curr Atheroscler Rep"},{"issue":"6","key":"10.1016\/j.jacl.2025.05.004_bib0005","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/MOL.0000000000000849","article-title":"Recent apolipoprotein CIII trials","volume":"33","author":"Tramontano","year":"2022","journal-title":"Curr Opin Lipidol"},{"issue":"6","key":"10.1016\/j.jacl.2025.05.004_bib0006","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2025.05.004_bib0007","unstructured":"https:\/\/ec.europa.eu\/health\/documents\/communityregister\/2021\/20210204150527\/anx_150527_it.pdf; Accessed April 14, 2025"},{"issue":"19","key":"10.1016\/j.jacl.2025.05.004_bib0008","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome","volume":"390","author":"Stroes","year":"2024","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jacl.2025.05.004_bib0009","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1080\/13543784.2016.1254187","article-title":"Lomitapide for the treatment of hypertriglyceridemia","volume":"25","author":"Brahm","year":"2016","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jacl.2025.05.004_bib0010","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.atherosclerosis.2022.08.017","article-title":"Efficacy and safety of lomitapide in familial chylomicronaemia syndrome","volume":"359","author":"Cefal\u00f9","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2025.05.004_bib0011","unstructured":"https:\/\/www.gazzettaufficiale.it\/atto\/serie_generale\/caricaDettaglioAtto\/originario?atto.dataPubblicazioneGazzetta=2023-0306&atto.codiceRedazionale=23A01444&elenco30giorni=false; Accessed April 14, 2025"},{"issue":"3","key":"10.1016\/j.jacl.2025.05.004_bib0012","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1001\/jamainternmed.2013.13309","article-title":"Severe hypertriglyceridemia with pancreatitis: thirteen years' treatment with lomitapide","volume":"174","author":"Sacks","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"3","key":"10.1016\/j.jacl.2025.05.004_bib0013","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jacl.2023.03.007","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: long-term efficacy and safety data from patients in an open-label extension trial","volume":"17","author":"Witztum","year":"2023","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.05.004_bib0014","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.atherosclerosis.2016.12.018","article-title":"Non-alcoholic fatty liver disease and subclinical atherosclerosis: A comparison of metabolically- versus genetically-driven excess fat hepatic storage","volume":"257","author":"Di Costanzo","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2025.05.004_bib0015","article-title":"Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","year":"2024","journal-title":"J Hepatol. Published online"},{"key":"10.1016\/j.jacl.2025.05.004_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2025.03.015","article-title":"Long-term experience with lomitapide treatment in patients with homozygous familial hypercholesterolemia: over ten years of efficacy and safety data","author":"Arca","year":"2025","journal-title":"J Clin Lipidol"},{"issue":"3","key":"10.1016\/j.jacl.2025.05.004_bib0017","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1161\/CIRCULATIONAHA.117.028208","article-title":"Long-term efficacy and safety of the microsomal triglyceride transfer protein inhibitor lomitapide in patients with homozygous familial hypercholesterolemia","volume":"136","author":"Blom","year":"2017","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jacl.2025.05.004_bib0018","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/eurjpc\/zwab229","article-title":"Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study","volume":"29","author":"D'Erasmo","year":"2022","journal-title":"Eur J Prev Cardiol"},{"issue":"2","key":"10.1016\/j.jacl.2025.05.004_bib0019","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/liv.15497","article-title":"Long-term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia","volume":"43","author":"Larrey","year":"2023","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.jacl.2025.05.004_bib0020","doi-asserted-by":"crossref","first-page":"669","DOI":"10.3390\/jcm10040669","article-title":"Non-alcoholic fatty liver in patients with chylomicronemia","volume":"10","author":"Maltais","year":"2021","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.jacl.2025.05.004_bib0021","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jacl.2023.05.096","article-title":"Non-alcoholic fatty liver disease in patients with chylomicronemia syndromes","volume":"17","author":"De Villers-Lacasse","year":"2023","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.05.004_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2022.967899","article-title":"Expanding the phenotypic spectrum of non-alcoholic fatty liver disease and hypertriglyceridemia","volume":"9","author":"Meroni","year":"2022","journal-title":"Front Nutr"},{"issue":"2","key":"10.1016\/j.jacl.2025.05.004_bib0023","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s12020-020-02506-y","article-title":"Effectiveness and safety of lomitapide in a patient with familial chylomicronemia syndrome","volume":"71","author":"Cefal\u00f9","year":"2021","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.jacl.2025.05.004_bib0024","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.numecd.2015.11.001","article-title":"Individual analysis of patients with HoFH participating in a phase 3 trial with lomitapide: the Italian cohort","volume":"26","author":"Averna","year":"2016","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.jacl.2025.05.004_bib0025","article-title":"Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNA","author":"Brinton","year":"2025","journal-title":"Atherosclerosis"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425002867?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425002867?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T03:56:06Z","timestamp":1749614166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287425002867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":25,"alternative-id":["S1933287425002867"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2025.05.004","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lomitapide-induced fatty liver is a reversible condition: Evidence from a case of familial chylomicronemia syndrome","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2025.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}